Nitromed Inc

Nitromed — JP Morgan Healthcare Conference 2004

28 slides from Nitromed's conference presentation, Jan 12, 2004

  1. Slide 1: Creating Nitric Oxide Enhancing Medicines

    Slide 1: Creating Nitric Oxide Enhancing Medicines

    ® NITROMED Creating Nitric Oxide Enhancing Medicines JP Morgan Healthcare Conference January 12, 2004 Michael D. Loberg, Ph.D. President and CEO

  2. Slide 2: Forward Looking Statement

    Slide 2: Forward Looking Statement

    Forward Looking Statement Any remarks that we may make about NitroMed’s future expectations, progress, plans, prospects, and target dates for research, development and clinical trial milestones, regulatory submissions, marketing approvals and product launches constitute forward looking statements fo

  3. Slide 3: NitroMed Highlights

    Slide 3: NitroMed Highlights

    NitroMed Highlights Leader in Nitric Oxide-based drug development * Near-term commercial opportunity - BiDil® * Active strategic collaborations — merck gBostone. ¢ Transitioning to integrated pharmaceutical company S@witronso

  4. Slide 4: NitroMed Update

    Slide 4: NitroMed Update

    NitroMed Update ¢ Merck and NitroMed advanced lead NO-based COX-2 Inhibitor into Phase I testing; $5MM milestone payment * Boston Scientific and NitroMed extended NO drug coated stent agreement for 2 more years; $3MM R&D payment * BiDil® confirmatory clinical trial recruitment on schedule; expected

  5. Slide 5: BiDil

    Slide 5: BiDil

    BiDil® (Isosorbide Dinitrate and Hydralazine) NO-Enhancing Medicine To Treat African Americans with Heart Failure ~ @Qniteomeo

  6. Slide 6: BiDil: Attractive Commercial Potential

    Slide 6: BiDil: Attractive Commercial Potential

    Bibi® oe To reduce mortality and hospitalizations and improve quality-of-life in African Americans with heart failure Attractive Commercial Potential ¢ Large, unmet medical need First-in-class Nitric Oxide Enhancing therapy ¢ Pricing flexibility « Reached by focused sales force ~ @nitaoneo

  7. Slide 7: Heart failure mortality by race (deaths per 100,000)

    Slide 7: Heart failure mortality by race (deaths per 100,000)

    i) ral 2 =) fe) 3] 5 sal a 3) 5 o co 2 @ ® a (9) < = re} a o Z ig w i=] i=] Deaths per 100,000 N i=] i=] ~ @Qniteomeo oS Black Males | White Males SS Black Females White Females “80 ‘88 ‘92 ‘96 USS. Dept. of Health Statistics, 1998

  8. Slide 8: Heart Failure In African Americans

    Slide 8: Heart Failure In African Americans

    Heart Failure In African Americans owe e African Americans suffer disproportionately - 18% of the disease; 11% of the population e African Americans experience unique etiology — younger age — lower incidence of coronary artery disease — higher incidence of hypertension e Altered response to approved

  9. Slide 9: CV Market in AAs is Underserved

    Slide 9: CV Market in AAs is Underserved

    CV Market in AAs is Underserved owe in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non- blacks” .... “black patients ... have a higher incidence of angioedema compared to non-blacks.” Se ee cane ais ™... the LIFE study provides n

  10. Slide 10: BiDil: First In Class HF Medication

    Slide 10: BiDil: First In Class HF Medication

    BiDiI®: First In Class HF Medication owe Heart Failure is Associated with Neu Excess and Nitric Oxide Insuffi + Beta Blockers + Renin-Angiotensin Antagonists Neurohormonal Antagonists | + Aldosterone Blockers Nitric Oxide Enhancers | + BiDil; pending approval ~ @nitaoneo

  11. Slide 11: Attractive Commercial Potential

    Slide 11: Attractive Commercial Potential

    Attractive Commercial Potential owe e U.S. heart failure market ~$50 billion annually e BiDil market opportunity ~ 0.9 MM diagnosed AA heart failure patients at current Coreg pricing ($3.40/day) ~ $1.1 billion market opportunity e Relatively easy to penetrate — add-on therapy — expected to be only d

  12. Slide 12: Extensive BiDil Clinical Data

    Slide 12: Extensive BiDil Clinical Data

    Extensive BiDil Clinical Data owe « Two, six-year mortality trials in heart failure patients — 1,446 patients; 395 of which were AA ¢ Medco research analyzed data without regard to race — received a FDA non-approvable letter in 1997, p<0.06 « NitroMed — analyzed the clinical data by race, — reviewed

  13. Slide 13: Survival Benefit in African Americans

    Slide 13: Survival Benefit in African Americans

    Survival Benefit in African Americans owe Non-African Americans African Americans 280% 370% < 260% coe 0.0% 6 12 18 24 30 36 42 48 54 60 66 Months Cumulative mortality 0.0% 5 O 6 12 18 24 30 36 42.48 54 60 66 Months — BiDil® ~ @nitaoneo — PLACEBO

  14. Slide 14: FDA Response

    Slide 14: FDA Response

    FDA Response owe “... a single, clearly positive study in a black CHF population would be a basis for approval of BiDil® for the treatment of heart failure in blacks.” “... if the results of the study are convincing this would provide sufficient clinical evidence to support approval of BiDil®.” Robe

  15. Slide 15: A-HeFT: African-American Heart Failure Trial

    Slide 15: A-HeFT: African-American Heart Failure Trial

    bee A-HeFT African-American Heart Failure Trial A PLACEBO-CONTROLLED TRIAL OF BIDIL® ADDED TO STANDARD THERAPY IN AFRICAN-AMERICAN PATIENTS WITH HEART FAILURE ~ @Qniteomeo

  16. Slide 16: A-HeFT Trial Summary

    Slide 16: A-HeFT Trial Summary

    A-HeFT Trial Summary owe ¢ Trial in 1,100 class III/IV AA heart failure patients ¢ BiDil additive to all standard therapies ¢ Combined endpoint of mortality, hospitalization and quality- of-life ¢ DSMB interim analysis on first 313 patients — No significant adverse reactions - 900 patients required

  17. Slide 17: BiDil Coalition

    Slide 17: BiDil Coalition

    BiDil® Coalition Association of Black Cardiologists, Inc. MA) National 2 | Medical Association’ ~ @Qniteomeo

  18. Slide 18: BiDil - Near Term Commercialization

    Slide 18: BiDil - Near Term Commercialization

    BiDil® - Near Term Commercialization « Attractive commercial potential — large, unmet medical need — first-in-class therapy — pricing flexibility — reachable by focused sales force « FDA approval dependent on A-HeFT — large body of NDA data © Approval risk mitigated — positive A-HeFT interim results

  19. Slide 19: Our Pipeline and Strategic Collaborations

    Slide 19: Our Pipeline and Strategic Collaborations

    Our Pipeline and Strategic Collaborations Making the best medicines better, 4@nizaowen

  20. Slide 20: Merck NO-based COX-2 Inhibitors

    Slide 20: Merck NO-based COX-2 Inhibitors

    merck NO-based COX-2 Inhibitors = Exclusive WW research and licensing collaboration NO-Based COX-2 inhibitors — improved GI and renal profiles — extensive NitroMed IP - $6 Billion market Lead candidate in Phase I clinical testing Two milestones and $23 million income in 2003 Potential of up to $350

  21. Slide 21: Boston Scientific NO-Coated Stent

    Slide 21: Boston Scientific NO-Coated Stent

    Seine NO-Coated Stent ¢ Exclusive research & development license agreement — extended for additional 2 years in January 2004 — 3 products Nitric Oxide properties used to reduce restenosis — antiplatelet, antiproliferative and promotes vascular re-endothelializaton $6.8 billion market in 2006 Extensi

  22. Slide 22: Future Pipeline Candidates

    Slide 22: Future Pipeline Candidates

    Future Pipeline Candidates U.S, Patents Issued Pending Cardiovascular 13 5 — Aspirin plus NO-Donor — NO-Enhancing Statins — NO-Enhancing ACE Inhibitors Pain & Inflammation 15 3 — NO-Enhancing NSAIDs — NO-Enhancing Steroids Pulmonary 14 1 — NO-Enhancing PDE inhibitors S@witronso

  23. Slide 23: NitroMed Corporate Details

    Slide 23: NitroMed Corporate Details

    NitroMed Corporate Details 4@nizaowen

  24. Slide 24: Financial Guidance

    Slide 24: Financial Guidance

    FINANCIAL GUIDANCE ¢ 2003 Year-End Financial Guidance — total R&D Revenue of $12 to $13 MM — total Operating Expenses of $21 to $24 MM — Cash & Marketable Securities of $96 to $98 MM © 2004 Year-End Financial Guidance — total R&D Revenue of $8 to $10 MM — total Operating Expenses of $28 to $33 MM —

  25. Slide 25: Anticipated Upcoming Milestones

    Slide 25: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones BiDil € MERCK Product Development ~ @niteoneo Interim Safety Assessment Close of Recruitment Clinical Results NDA Supplement Filing BiDil Launch ‘assuming FOA approval Phase | Trial Initiated Stent Trials New Pharma Deals Q1 2004 Q3 2004 Q2 2005 Q3 2005 Q1 2006 Q4 200

  26. Slide 26: Company Highlights

    Slide 26: Company Highlights

    Company Highlights ¢ Late stage BiDil opportunity — large, unsatisfied market — reduced development risk — all commercial rights retained * Strong strategic collaborations merc Boston. — large markets - . — market leaders ¢ Inherently lower-risk business model — leading patent position — multiple pr

  27. Slide 27: NitroMed Management

    Slide 27: NitroMed Management

    NitroMed Management Name Jerry Karabelas, Ph.D. Michael D. Loberg, Ph.D Manuel Worcel, M.D. L. Gordon Letts, Ph.D Joseph Grimm, M.B.A. S@witronso Position Non-Exec Chairman, Partner Care Capital CEO & President Chief Medical Officer Senior VP & CSO Senior VP & CFO Previous Affi Novartis Bristol-Myer

  28. Slide 28: Searchable text section of graphics

    Slide 28: Searchable text section of graphics

    Searchable text section of graphics shown above [ LOG O] Creating Nitric Oxide Enhancing Medicines [GRAPHIC] JP Morgan Healthcare Conference January 12, 2004 Michael D. Loberg, Ph.D. President and CEO For ward Looking Statement [GRAPHIC] Any remarks that we may make about NitroMed’s future expectati

Source: SEC EDGAR · 8-K filed Jan 12, 2004

More decks from Nitromed Inc